Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T790M Positive NSCLC Patients”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Testing effectiveness (Phase 2)Study completedNCT03812809
What this trial is testing

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Who this might be right for
NSCLC
Beta Pharma Shanghai 226
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)UnknownNCT04316351
What this trial is testing

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Guangzhou Institute of Respiratory Disease 60
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Not applicableStudy completedNCT03457220
What this trial is testing

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 423
Testing effectiveness (Phase 2)Study completedNCT03046992
What this trial is testing

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Gene Mutation
Yuhan Corporation 224
Testing effectiveness (Phase 2)Ended earlyNCT02485652
What this trial is testing

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 162
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Testing effectiveness (Phase 2)UnknownNCT03300115
What this trial is testing

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 222
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)UnknownNCT02330367
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 368
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Testing effectiveness (Phase 2)Study completedNCT03513666
What this trial is testing

Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 40
Not applicableStudy completedNCT02777567
What this trial is testing

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 315
Early research (Phase 1)Ended earlyNCT04622072
What this trial is testing

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Sihuan Pharmaceutical Holdings Group Ltd. 21
Load More Results